Puma Biotechnology director Troy Wilson sells $45,500 in stock

Puma Biotechnology director Troy Wilson sold 5,000 shares of the company's stock on September 14, 2026, under a prearranged trading plan. The transaction was worth $45,500 and involved selling the shares at $9.1 per share, slightly below the current trading price of $9.39 and close to the stock's 52-week high of $9.73. This comes after the stock experienced a 116% increase over the past year, climbing from a low of $4.30.

Following the sale, Wilson directly holds 54,750 shares of Puma Biotechnology common stock, as well as 400 shares indirectly through his children. Analysts consider PBYI undervalued at the moment, trading under its Fair Value, with a financial health score of 3.5 out of 5. For those interested in more detailed analysis, a Pro Research Report is available for PBYI and 1,400+ other US equities.

Recently, Puma Biotechnology reported better-than-expected earnings for Q2 2026, with revenue of $56.5 million, beating expectations of $52 million, and GAAP earnings of $0.16 per diluted share, significantly above the forecasted $0.03 per share. This marks a return to profitability for the company after a loss in the prior quarter, driven by strong sales of their product NERLYNX.